Advanced Search

Journal of Traditional Chinese Medicine >

2023 , Vol. 43 >Issue 5: 1001 - 1009

DOI: https://doi.org/10.19852/j.cnki.jtcm.20230802.001

Mechanism of Lingbao Huxin Dan (灵宝护心丹) in the treatment of bradyarrhythmia complicated with coronary heart disease: a network pharmacology analysis

  • Huagang HAN ,
  • Ziqiang LI ,
  • Jingfeng OUYANG ,
  • Tianquan WANG ,
  • Lingyan DONG ,
  • Junling CAO
Expand
  • 1 Department of Traditional Chinese Medicine, Nanyang Medical College, Nanyang 473061, China
    2 Oncology Department, Luoyang Hospital of traditional Chinese Medicine, Luoyang 471099, China
    3 Morphology Laboratory, Expeimental Research Center, Research and Development Service Base, Beijing Key Laboratory of Research of Chinese Medicine on Prevention and Treatment for Major Diseases, China Academy of Chinese Medical Sciences, Beijing 100700, China
    4 Pharmaceutical Department, Dongfang Hospital of Beijing University of Traditional Chinese Medicine, Beijing 100078, China
    5 Pharmaceutical Department, Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine, Beijing 100700, China

Received date: 2022-09-12

  Accepted date: 2022-12-22

  Online published: 2023-08-02

Supported by

Training Project of National Administration of Traditional Chinese Medicine “Natural Training Project of Backbone of Traditional Chinese Medicine” (SATCM)(2019-128);Fundamental Research Funds for the Central Public Welfare Research Institutes: the Application of Panoramic Tissue Scanning and Quantitative Analysis Systems in the Research of Traditional Chinese Medicine for Disease Prevention and Treatment”(JBGS2021005)

Fold

Abstract

OBJECTIVE: To investigate the mechanism of action of the Lingbao Huxin Dan (灵宝护心丹) in treating bradycardia arrhythmia with coronary heart disease (BA-CHD) by network pharmacology.
METHODS: The active ingredients of the Lingbao Huxin Dan were screened on the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform and Bioinformatics tools designed for the analysis of molecular mechanisms of Chinese medicine platform; target prediction was conducted with the SwissTargetPrediction database, and Cytoscape 3.8 was used to construct a drug ingredient-target network. The Genecards, Online Mendelian Inheritance in Man, and DrugBank databases were searched for disease targets. Venn plots were used to display the common targets of BA-CHD and active ingredients. The STRING platform was used to construct a protein-protein interaction network. The Metascape data platform was used for Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis to construct a signaling pathway network of the active ingredients of the Lingbao Huxin Dan.
RESULTS: There were 121 active ingredients, 899 related targets, 39 targets important in BA-CHD and 14 targets which intersected between the active ingredients and BA-CHD. There were 27 core therapeutic ingredients, 153 biological processes, 18 cell ingredients and 20 molecular functions obtained by GO enrichment analysis. The KEGG pathway analysis yielded 19 signaling pathways.
CONCLUSION: RBA-CHD may treat BA-CHD by regulating adrenergic receptor beta-1, alpha 1-α adrenergic receptor, calcium voltage-gated channel subunit alpha1 C, alpha-1β-adrenergic receptor, nitric oxide synthase 2, beta-2 adrenergic receptor, voltage-dependent calcium channel subunit alpha-2/delta-1, an- giotensin-converting enzyme, Raf-1 proto-oncogene serine/threonine-protein kinase, and other targets, potentially by affecting adrenergic receptor binding and calcium channel opening, to regulate the activity of cardiomyocytes.

Key words： bradycardia; coronary disease; network pharmacology; Lingbao Huxin Dan

Cite this article

Huagang HAN , Ziqiang LI , Jingfeng OUYANG , Tianquan WANG , Lingyan DONG , Junling CAO . Mechanism of Lingbao Huxin Dan (灵宝护心丹) in the treatment of bradyarrhythmia complicated with coronary heart disease: a network pharmacology analysis[J]. Journal of Traditional Chinese Medicine, 2023 , 43(5) : 1001 -1009 . DOI: 10.19852/j.cnki.jtcm.20230802.001

References

1. Lin GW, Wang JY, Ge JB. Practical Internal Medicine. Beijing: People's Health Publishing House, 2017: 837.
2. Chen Y, Xiao X, Xu XL, Zhang ZP, Deng Y. Traditional Chinese Medicine in the prevention and treatment of stable angina pectoris in patients with coronary heart disease based on the theoryof "phlegm and blood stasis" under guidance of evidence-based medicine: a prospective cohort study. J Tradit Chin Med 2021; 41: 150-6.
3. Wu YL. Observation of therapeutic effect of huxindan on sick sinus syndrome. Zhong Xi Yi Jie He Za Zhi 1987; 11: 682-3.
4. Liu WM, Xia CH, Ding YZ. Observation on the short-term curative effect of huxindan on sick sinus syndrome. Zhong Xi Yi Jie He Za Zhi 1984; 10: 590-2, 78.
5. Hua GY. Lingbao Huxin Dan, a new cardiovascular Chinese patent medicine. Hubei Yi Xue Zhi Nan 1987; 1: 27
6. Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform 2014; 6: 13.
7. Liu ZY, Guo FF, Wang Y, Li C, et al. BATMAN-TCM: a bioinformatics analysis tool for molecular mechanism of Traditional Chinese Medicine. Sci Rep 2016; 6: 21146.
8. Daina A, Michielin O, Zoete V. SwissTarget Prediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucl Acids Res 2019; 47: W357-64.
9. Li HL, Huang JS, Liu CH, et al. A new model of heart failure post-myocardial infarction in the rat. J Vis Exp 2021; (172). doi: 10.3791/62540.
10. Zhang XL, Li J, Zhou XL, et al. Effect of Erxian decoction on autoimmune premature ovarian failure in mice. J Tradit Chin Med 2021; 41: 725-31.
11. Li YQ, Wang J, Li XX, Ma XH, Li ZY. Pathogenesis of bradyarrhythmia and current situation of Traditional Chinese and Western Medicine treatment. Yi Xue Zong Shu 2019; 25: 3221-6, 31.
12. Wang SN, Hou P. Progress in the treatment of coronary heart disease with bradyarrhythmia. Shi Yong Zhong Yi Za Zhi 2019; 33: 103-5.
13. Jin LZ, Hou P. Research progress of Traditional Chinese Medicine in the treatment of coronary heart disease complicated with bradyarrhythmia. Neimenggu Zhong Yi Yao 2017; 36: 152-4.
14. Wang BB, Cao Y, Cui AC, Wang XF. Research progress of Traditional Chinese Medicine on bradyarrhythmia. Xin Jiang Zhong Yi Yao 2020; 38: 117-20.
15. Chen YL, Hao YY, Guo FJ, Bian XL, Wu YC, Li YM. Research progress on chemical constituents and pharmacological activities of toad venom. Zhong Cao Yao 2017; 48: 2579-88.
16. Liu L, Li XH, Wang W, et al. Epinephrine antagonizes arrhythmia induced by Shuanghuanglian injection. Zhong Guo Yao Li Xue Yu Du Li Xue Za Zhi 2014; 28: 334-9.
17. Wang H, Deng CY, Rao F, et al. Mechanism of 5-hydroxytryptamine induced coronary artery contraction. Zhong Guo Bing Li Sheng Li Za Zhi 2018; 34: 825-31.
18. Zhang YQ, Ma JH, Zhang PH, Ouyang JP. Effects of gamma aminobutyric acid and morphine injection into nucleus tractus solitarius on bradycardia induced by aortic nerve stimulation. Hubei Yi Ke Da Xue Za Zhi 1999; 2: 92-4, 7.
19. Qu CH. Pharmacological study and clinical application of cinobufacini injection. Shi Zhen Guo Yi Guo Yao 1999; 5: 67-8.
20. Wan XH, Wang YL, Zhou CZ, et al. Research progress on chemical constituents and pharmacological effects of Salvia miltiorrhiza. Zhong Cao Yao 2020; 51: 788-98.
21. Yan N, Yang CX, Ma J, et al. Effects of β-sitosterol on myocardial ischemia-reperfusion injury and ERK1/2 signaling pathway in rats. Xin Xue Guan Bing Xue Jin Zhan 2020; 41: 321-5.
22. Guan KX, Wang WJ, Li ZJ, et al. Adrenergic receptor and cardiovascular disease. Zhong Guo Ke Xue: Sheng Ming Ke Xue 2020; 50: 791-801.
23. Zhang T, Jia L, Liu C, et al. L-type calcium channel α (1c) protein expression in canine pulmonary vein vestibule. Zhong Guo Xian Dai Yi Xue Za Zhi 2009; 19: 2426-8.
24. Xue QF, Wang ZG. α-voltage dependent calcium channel 2 δ subunits and diseases and drug targets. Zhong Guo Shi Yong Yi Yao 2007; 34: 1-3.
25. Velkoska E, Patel SK, Burrell LM. Angiotensin converting enzyme 2 and diminazene: role in cardiovascular and blood pressure regulation. Curr Opin Nephrol Hypertens 2016; 25: 384-95.
26. Huang FF, Ye Y, Xu CX, et al. Effect of Jianxin granule on nitric oxide synthase in rats with chronic heart failure. Zhong Xi Yi Jie He Xin Nao Xue Guan Za Zhi 2009; 7: 186-8.
27. Zheng YP, Liu CJ. Construction of recombinant adenovirus siRNA vector of Raf-1 gene and its effect on rat cardiomyocyte hypertrophy. Zhong Guo Bi Jiao Yi Xue Za Zhi 2016; 26: 18-23.
28. Xiao RP. Beta-adrenergic signaling in the heart: dual coupling of the beta2-adrenergic receptor to G(s) and G(i) proteins. Sci STKE 2001; 2001: re15.
29. Francis SH, Busch JL, Corbin JD, Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 2010; 62: 525-63.
30. Takimoto E. Cyclic GMP-dependent signaling in cardiac myocytes. Cir J 2012; 76: 1819-25.
31. Keef KD, Hume JR, Zhong J. Regulation of cardiac and smooth muscle Ca(2+) channels (Ca(V)1.2a, b) by protein kinases. Am J Physiol Cell Physiol 2001; 281: C1743-56.
Options
Outlines

/

〈 〉